Cost-effectiveness of ruxolitinib vs. Best Available Therapy in the treatment of myelofibrosis in Spain

Autores: : Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, Martínez-López J, Ferrario MG, Gozalbo Irmina, Gostkorzewicz J, Subirá R

Diario: Journal of Health Economics & Outcomes Research (JHEOR)

Año: 2017

Referencia cientifica: JHEOR 2017;5(2):162-74